Reprint
Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration
Edited by
April 2022
246 pages
- ISBN978-3-0365-3930-0 (Hardback)
- ISBN978-3-0365-3929-4 (PDF)
This book is a reprint of the Special Issue Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
aflibercept monotherapy; polypoidal choroidal vasculopathy; neovascular age-related macular degeneration; good baseline visual acuity; ForeseeHome AMD Monitoring System®; neovascular age-related macular degeneration; AREDS2-HOME study; age-related macular degeneration; exudation; optical coherence tomography angiography; age-related macular degeneration; anti-vascular endothelial growth factor; brolucizumab; epithelial tear; exudation; optical coherence tomography; Sorsby’s fundus dystrophy; Sorsby; hereditary retinal dystrophy; choroidal neovascularisation; macular neovascularization; anti-VEGF treatment; long-term FU; treatment outcome; emerging treatment; neovascular age-related macular degeneration (nAMD); Vascular Endothelial Growth Factor (VEGF); cataract surgery; age-related macular degeneration; clinical trials; real-world evidence; AMD; oct-angiography; fellow eye; choriocapillaris; quiescent macular neovascularization; brolucizumab; ranibizumab; aflibercept; anti-VEGF; neovascular age-related macular degeneration; visual acuity; reading acuity; disease activity; treatment change; treat and extend; age-related macular degeneration; anti-vascular endothelial growth factor; brolucizumab; exudation; switch therapy; retina; choroidal neovascularization; angiogenesis; meteorin; therapeutic innovation; age-related macular degeneration; prevention; nutrients; lifestyle; age-related macular degeneration; anti-vascular endothelial growth factor; brolucizumab; exudation; treatment-naive; age-related macular degeneration; anti–vascular endothelial growth factor; cardiovascular risk factors; arterial hypertension; macula-off rhegmatogenous detachment; optical coherence tomography angiography; superficial perifoveal capillary plexus; retinal deep perifoveal capillary plexus; age-related macular degeneration; prevention; identification; risk; Delphi; STARS®; food supplement; aflibercept; age-related macular degeneration; anti-VEGF; bevacizumab; brolucizumab; meta-analysis; meta-regression; ranibizumab; n/a; age-related macular degeneration (AMD); aflibercept; comparative therapies; effectiveness; intravitreal anti-vascular endothelial growth factor; meta-analysis; ranibizumab; treat-and-extend; pro re nata regimen